Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05514210
Other study ID # 2022-1749
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 20, 2023
Est. completion date December 31, 2024

Study information

Verified date June 2023
Source China National Center for Cardiovascular Diseases
Contact Zhe Zheng, MD,PhD
Phone +86-010-88396051
Email zhengzhe@fuwai.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed to evaluate the clinical outcomes, efficiency and feasibility of the real-time heart team approach and the conventional heart team approach.


Description:

This study is a multicenter, randomized controlled trial. According to the inclusion and exclusion criteria, patients with complex coronary artery disease undergoing elective coronary angiography will be prospectively enrolled in the study. Patients will be randomly assigned to the real-time heart team group and the conventional heart team group by block randomization. The real-time heart team group needs to conduct multidisciplinary heart team discussion during the coronary angiography process, while the traditional heart team group needs to conduct multidisciplinary heart team discussion offline and face-to-face after the coronary angiography process. Patients who are not randomized will be registered. This study will prospectively collect the patient information, heart team meeting process, clinical treatment, and clinical outcomes to evaluate the efficiency and feasibility and differences in clinical outcomes of patients under different heart team approaches.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 490
Est. completion date December 31, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Significant stenosis in the left main or left main equivalent with or without stenosis in one of the other vessels[Significant stenosis is defined as: 1) a diameter stenosis of at least 50% reduction in luminal diameter by visual assessment or 2) any total occlusion (no age limitation and no exclusion of unfavorable anatomic features); Left main equivalent disease is defined as significant stenosis of the ostium of the left anterior descending and the ostium of the left circumflex.] 2. At least 1 significant stenosis in all 3 major epicardial territories supplying viable myocardium; 3. Other conditions that the interventional cardiologist considers necessary to discuss with cardiac surgeons due to technical and risk considerations. Exclusion Criteria: 1. Less than 18 years of age; 2. Previous history of PCI or CABG; 3. Admitted for AMI, ECG and biomarker detection indicated acute stage; 4. Patients with severe heart valvular disease, major vascular disease, and giant ventricular aneurysm require surgical treatment; 5. Combined with AF or severe arrhythmia; 6. Other patients admitted to hospital due to emergency circumstances who are not suitable to wait for elective revascularization; 7. Rejection or exclusion of a revascularization mode (PCI or CABG); 8. Refuse to participate in the study.

Study Design


Intervention

Behavioral:
heart team meeting and discussion
When the patient is eligible for the study, the interventional cardiologist will invite a cardiac surgeon to conduct a heart team discussion. Both specialists will assess the patient comprehensively and make an optimal decision for the patient, with consideration patient's preference.

Locations

Country Name City State
China China National Center for Cardiovascular Diseases Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1-year major adverse cardiovascular and cerebrovascular events a composite of all-cause death, myocardial infarction, stroke, repeated revascularization, ischemic symptoms with hospital admission. At 1 year after the coronary angiography
Secondary time interval between the completion of coronary angiography and the final treatment time interval is considered as a key secondary outcome through study completion, an average of 1 year
Secondary the appropriateness rate of heart team decisions assessment of the heart team dicision appropriateness according to Appropriateness Use Criteria and guidelines through study completion, an average of 1 year
Secondary heart team decision distribution assessment of the heart team dicision distribution, such as the rate of CABG, PCI, and medical treatment through study completion, an average of 1 year
Secondary working load of organizing heart team meetings to assess the work load of arganising heart team meetings by NASA-TLX through study completion, an average of 1 year
Secondary success rate of heart team organization to assess the successful-connection with cardiac surgeons during or after the coronary angiography through study completion, an average of 1 year
Secondary time consuming of heart team discussions to assess the time consuming of heart team organization and discussion during or after the coronary angiography through study completion, an average of 1 year
Secondary length of stay to assess length of stay (LOS) before the final treatment, and the totol LOS in hospital through study completion, an average of 1 year
Secondary total cost to assess the total cost in hospital for the initial hospitalization and rehospitalization through study completion, an average of 3 year
Secondary time interval of each diagnosis and treatment procedures to assess the time consuming of the angiography to heart team meeting time and heart team meeting to final treatment time through study completion, an average of 1 year
Secondary individual clinical adverse events including all-cause death, cardiac death, myocardial infarction, stroke, revascularization of target vessels or transplanted vessels, revascularization for any reason, be admitted to hospital with angina again, readmission for cardiac reasons and readmission for any reason At 1 year after the coronary angiography
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A